Save time and jump to the most important pieces.
Baron will align and advance NRC Health's experience solutions platform to solve health care industry challenges and continue effectively innovating and supporting experience improvement for health systems across the nation. NRC Health, a recognized leader providing solutions and data driven insights for improving health care experiences, announced today the appointment of Jennifer Baron as the organization's first chief experience officer. Baron's addition is part of the organization's continued investments in leadership and innovation to align with the evolving healthcare landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions. The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners. Four newly created executive leadership roles will guide NRC Health's strategy and success, including: Helen Hrdy, Chief Customer Officer Jason Hahn, Chief Revenue Officer Christophe Louvion, Chief Product Technology Officer Andy Monnich, Chief Corporate Development Officer "Strong leadership is key in driving innovation and meeting the ever-evolv
LINCOLN, Neb., May 19, 2022 (GLOBE NEWSWIRE) -- National Research Corporation, doing business as NRC Health ("NRC Health," "NRC", the "Company), the leading provider of in-depth customer insights in healthcare, today announced the appointment of Parul Bhandari to its Board of Directors, effective immediately. "Along with the rest of the Board, we are excited to share that Parul Bhandari has joined NRC Health as our newest Director," said NRC Health CEO Michael Hays. "Parul is an accomplished technology leader who brings a wealth of expertise on leveraging data and AI for positive impact to her new board role. Her experience driving industry solutions and engaging in digital transformati
National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $35.8 million compared with approximately $37.9 million in the 2023 quarter. Earnings per diluted share were $0.24 compared with $0.32 for the 2023 quarter. At September 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $50.2 million. Total recurring contract value (TRCV) was approximately $131.6 million at September 30, 2024. Dividends and Stock Repurchases During the quarter, the Company returned approximately $11.5 million t
Today, at NRC Health's 30th annual conference, Human Understanding Beyond | HUB24, the organization debuted healthcare's most comprehensive experience management platform and announced strategic acquisitions and partnerships to enable greater human connection across the healthcare journey. NRC Health, a recognized leader in delivering innovative solutions and data-driven insights to improve healthcare experiences, announced a new suite of next-gen AI-enabled products, along with an acquisition and new partnership, today at HUB24. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240822567645/en/Today, at NRC Health's 30th annual
National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2024 and several other corporate developments. Financial Results Revenue for the quarter was approximately $35 million compared with approximately $36 million in the 2023 quarter. Earnings per diluted share were $0.26 compared with $0.29 for the 2023 quarter. At June 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $42 million. Total recurring contract value (TRCV) was approximately $138 million at June 30, 2024. Credit Agreement Amendment Effective August 5, 2024, the Company and its lender entered into a Third Amendm
National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $35.8 million compared with approximately $37.9 million in the 2023 quarter. Earnings per diluted share were $0.24 compared with $0.32 for the 2023 quarter. At September 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $50.2 million. Total recurring contract value (TRCV) was approximately $131.6 million at September 30, 2024. Dividends and Stock Repurchases During the quarter, the Company returned approximately $11.5 million t
National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2024 and several other corporate developments. Financial Results Revenue for the quarter was approximately $35 million compared with approximately $36 million in the 2023 quarter. Earnings per diluted share were $0.26 compared with $0.29 for the 2023 quarter. At June 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $42 million. Total recurring contract value (TRCV) was approximately $138 million at June 30, 2024. Credit Agreement Amendment Effective August 5, 2024, the Company and its lender entered into a Third Amendm
National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: "NRC continues to be strongly positioned for growth in our expanding markets. Our decades of benchmarks and trusted thought leadership afford healthcare insights unavailable to most competitors, while our client service remains unmatched, and we continue to roll out innovative new products and technologies. Our mission to enhance outcomes and experiences for everyone in the healthcare journey, while improving our clients' bottom lines, provides true alignment with our clients. "Healthcare systems are facing unp
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Cassava Sciences Inc (NASDAQ:SAVA) On July 1, Cassava Sciences engaged the U.S. Department of Justice (DOJ) and the U.S. Secu
National Research (NASDAQ:NRC) reported quarterly earnings of $0.27 per share. This is a 3.57 percent decrease over earnings of $0.28 per share from the same period last year. The company reported $35.31 million in sales this quarter. This is a 3.18 percent decrease over sales of $36.47 million the same period last year.
National Research (NASDAQ:NRC) reported quarterly earnings of $0.36 per share. This is a 33.33 percent increase over earnings of $0.27 per share from the same period last year. The company reported $38.00 million in sales this quarter. This is a 0.37 percent decrease over sales of $38.14 million the same period last year.
SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)
SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)
SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)
4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)
4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)
4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)
8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)
8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)
10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)